One biotech company put the mission of this week’s Exponential Medicine Conference to work by proving that is is possible to deliver real-time, accurate DNA testing. Exponential Medicine is a unique four-day conference that gathers world-class faculty, innovators and entrepreneurs from across the biomedical and technology spectrum to “explore the convergence of fast moving technologies.” [Read more…]
In major news released today, ORIG3N announced that it has opened a new regenerative medicine laboratory and expanded headquarters in Boston.
Founded in 2014, ORIG3N is creating the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. It uses these blood cells to produce patient-specific iPSCs to grow different cell types, including heart cells (cardiomyocytes), liver cells (hepatocytes), brain cells (neurons), and more.
In addition to collecting donated blood samples for iPSC production, ORIG3N offers an optional LifeCapsule membership, in which individuals can pay $99/year to get permanent access to their own immortalized iPS cells. ORIG3N also has two other business units, LifeProfile and LifeSystems, which are discussed in detail in the interview below.
Learn more by reading the full press release below, printed with permission from Julie Hall, Managing Director of Havas Health and media contact for ORIG3N. [Read more…]
Founded in April 2014, ORIG3N is an interesting and innovative company that is developing the world’s largest uniformly consented blood cell repository, known as LifeCapsule. They are using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs). The company also has two other business segments, called LifeProfile and LifeSystems. As a newcomer to the biotech industry, there has been a great deal of activity going on at the company, which you can read more about in this fascinating interview with James Lovgren, Chief Business Officer of ORIG3N.
In major news released today, ORIG3N now announced that it will be presenting at the upcomingJ.P. Morgan/Biotech Showcase and named three new board members, Tom Mac Mahon, George Hara, and Justin Xiang. [Read more…]